Keywords: alexion, completes, enrollment, ph, ii, kidney, disease
Alexion completes enrollment in Ph II kidney disease trial
Article | 25 February 2002
Alexion has completed enrollment in a Phase II study of its complementC5 inhibitor eculizumab (formerly 5G1.1) in patients with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
